Phase 1 — Early testing in a small group of people (usually 20–80) to evaluate safety, determine safe dosage, and identify side effects.
Trial locations(7 sites)
Australia
Nucleus Network, Brisbane Nucleus Network, Melbourne China
Peking University First Hospital, Beijing Peking University Third Hospital, Beijing Xiangya Hospital of Central South University, Changsha Renji Hospital, Shanghai Jiaotong University School of Medicine, Shanghai Union Hospital Tongji Medical College Huazhong University of Science and Technology, Wuhan